Support
Dr. Goyal is supported by a project grant from the Australian National Health and Medical Research Council (NHMRC) project grant (number 1019834) and the NHMRC Centre for Research Excellence in Lung Health of Aboriginal and Torres Strait Islander Children (grant number 1040830). Prof. Chang is supported by the NHMRC practitioner fellowship (grant 545216). The views expressed in this publication are those of the authors and do not reflect the views of the NHMRC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aaron, S. D., Donaldson, G. C., Whitmore, G. A., Hurst, J. R., Ramsay, T., & Wedzicha, J. A. (2012). Time course and pattern of COPD exacerbation onset. Thorax, 67(3), 238–243. doi:10.1136/thoraxjnl-2011-200768.
Aaron, S. D., Vandemheen, K. L., Maltais, F., Field, S. K., Sin, D. D., Bourbeau, J., et al. (2013). TNFα antagonists for acute exacerbations of COPD: A randomised double-blind controlled trial. Thorax, 68(2), 142–148. doi:10.1136/thoraxjnl-2012-202432.
Advani, S., Sengupta, A., Forman, M., Valsamakis, A., & Milstone, A. M. (2012). Detecting respiratory viruses in asymptomatic children. Pediatric Infectious Disease Journal, 31(12), 1221–1226. doi:10.1097/INF.0b013e318265a804.
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., et al. (2011). Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine, 365(8), 689–698. doi:10.1056/NEJMoa1104623.
Anzueto, A., & Niederman, M. S. (2003). Diagnosis and treatment of rhinovirus respiratory infections. CHEST Journal, 123(5), 1664–1672. doi:10.1378/chest.123.5.1664.
Arden, K. E., Chang, A. B., Lambert, S. B., Nissen, M. D., Sloots, T. P., & Mackay, I. M. (2010). Newly identified respiratory viruses in children with asthma exacerbation not requiring admission to hospital. Journal of Medical Virology, 82(8), 1458–1461. doi:10.1002/jmv.21819.
Bach, P. B., Brown, C., Gelfand, S. E., McCrory, D. C., American College of Physicians-American Society of Internal Medicine, & American College of Chest Physicians. (2001). Management of acute exacerbations of chronic obstructive pulmonary disease: A summary and appraisal of published evidence. Annals of Internal Medicine, 134(7), 600–620.
Baines, K. J., Simpson, J. L., Wood, L. G., Scott, R. J., & Gibson, P. G. (2011). Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. The Journal of Allergy and Clinical Immunology, 127(1), 153–160, 160 e151–159. doi: 10.1016/j.jaci.2010.10.024.
Bains, S. N., & Judson, M. A. (2012). Allergic bronchopulmonary aspergillosis. Clinics in Chest Medicine, 33(2), 265–281. doi:10.1016/j.ccm.2012.02.003.
Barnig, C., & Casset, A. (2012). Respiratory allergens and asthma exacerbation. Revue des Maladies Respiratoires, 29(6), 810–819. doi:10.1016/j.rmr.2012.04.004.
Bhogal, S. K., McGillivray, D., Bourbeau, J., Benedetti, A., Bartlett, S., & Ducharme, F. M. (2012). Early administration of systemic corticosteroids reduces hospital admission rates for children with moderate and severe asthma exacerbation. Annals of Emergency Medicine, 60(1), 84–91 e83. doi:10.1016/j.annemergmed.2011.12.027.
Bischoff, E. W., Hamd, D. H., Sedeno, M., Benedetti, A., Schermer, T. R., Bernard, S., et al. (2011). Effects of written action plan adherence on COPD exacerbation recovery. Thorax, 66(1), 26–31. doi:10.1136/thx.2009.127621.
Black, P. N., Morgan-Day, A., McMillan, T. E., Poole, P. J., & Young, R. P. (2004). Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulmonary Medicine, 4, 13. doi:10.1186/1471-2466-4-13.
Brusselle, G. G., Vanderstichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V., et al. (2013). Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax. doi:10.1136/thoraxjnl-2012-202698.
Burness, C. B., & Keating, G. M. (2012). Mannitol dry powder for inhalation: In patients with cystic fibrosis. Drugs, 72(10), 1411–1421. doi:10.2165/11208950-000000000-00000.
Busse, W. W., Lemanske, R. F., Jr., & Gern, J. E. (2010). Role of viral respiratory infections in asthma and asthma exacerbations. The Lancet, 376(9743), 826–834. doi:10.1016/S0140-6736(10)61380-3.
Chang, A. B. (2011). Bronchiectasis: So much yet to learn and to do. Paediatric Respiratory Reviews, 12(2), 89–90. doi:10.1016/j.prrv.2011.01.001.
Chang, A. B., & Bilton, D. (2008). Exacerbations in cystic fibrosis: 4 · Non-cystic fibrosis bronchiectasis. Thorax, 63(3), 269–276. doi:10.1136/thx.2006.060913.
Chang, A. B., Redding, G. J., & Everard, M. L. (2008). Chronic wet cough: Protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatric Pulmonology, 43(6), 519–531. doi:10.1002/ppul.20821.
Chang, A. B., Bell, S. C., Byrnes, C. A., Grimwood, K., Holmes, P. W., King, P. T., et al. (2010). Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. The Medical Journal of Australia, 193(6), 356–365.
Chang, A. B., Marsh, R. L., Smith-Vaughan, H. C., & Hoffman, L. R. (2012). Emerging drugs for bronchiectasis. Expert Opinion on Emerging Drugs, 17(3), 361–378. doi:10.1517/14728214.2012.702755.
Chen, A. H., Chen, R. C., Zhan, J. Y., Huang, S., Lin, Y. N., Chen, D. H., et al. (2012). The efficacy of nebulized budesonide in acute moderate to severe exacerbations of asthma in children. Zhonghua Jie He He Hu Xi Za Zhi, 35(4), 269–274.
Chesnutt, M. S. (1998). Management of asthma exacerbations. Clinical Cornerstone, 1(2), 39–56. doi:10.1016/S1098-3597(98)80005-7.
Chew, K. S., Kamarudin, H., & Hashim, C. W. (2012). A randomized open-label trial on the use of budesonide/formoterol (Symbicort(R)) as an alternative reliever medication for mild to moderate asthmatic attacks. International Journal of Emergency Medicine, 5, 16. doi:10.1186/1865-1380-5-16.
Cole, P. J. (1986). Inflammation: A two-edged sword – The model of bronchiectasis. European Journal of Respiratory Diseases. Supplement, 147, 6–15.
Craig, A., Mai, J., Cai, S., & Jeyaseelan, S. (2009). Neutrophil recruitment to the lungs during bacterial pneumonia. Infection and Immunity, 77(2), 568–575. doi:10.1128/iai.00832-08.
Crockett, A. J., Cranston, J. M., Latimer, K. M., & Alpers, J. H. (2001). Mucolytics for bronchiectasis. Cochrane Database of Systematic Reviews, 1, CD001289. doi:10.1002/14651858.cd001289.
Davies, J. C., & Alton, E. W. (2009). Monitoring respiratory disease severity in cystic fibrosis. Respiratory Care, 54(5), 606–617.
Daviskas, E., Anderson, S. D., Gomes, K., Briffa, P., Cochrane, B., Chan, H. K., et al. (2005). Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: Effect on lung function, health status and sputum. Respirology, 10(1), 46–56. doi:10.1111/j.1440-1843.2005.00659.x.
Daviskas, E., Anderson, S. D., & Young, I. H. (2010). Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respiratory Medicine, 104(3), 371–377. doi:10.1016/j.rmed.2009.10.021.
de Almeida, M. B., Zerbinati, R. M., Tateno, A. F., Oliveira, C. M., Romao, R. M., Rodrigues, J. C., et al. (2010). Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerging Infectious Diseases, 16(6), 996–999. doi:10.3201/eid1606.100063.
Dickens, J. A., Miller, B. E., Edwards, L. D., Silverman, E. K., Lomas, D. A., Tal-Singer, R., et al. (2011). COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respiratory Research, 12, 146. doi:10.1186/1465-9921-12-146.
Didierlaurent, A., Goulding, J., Patel, S., Snelgrove, R., Low, L., Bebien, M., et al. (2008). Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. The Journal of Experimental Medicine, 205(2), 323–329. doi:10.1084/jem.20070891.
Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., & Boucher, R. C. (2006). Mucus clearance and lung function in cystic fibrosis with hypertonic saline. The New England Journal of Medicine, 354(3), 241–250. doi:10.1056/NEJMoa043891.
D’Silva, L., Hassan, N., Wang, H. Y., Kjarsgaard, M., Efthimiadis, A., Hargreave, F. E., et al. (2011). Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice. Canadian Respiratory Journal, 18(3), 144–148.
Duffy, N., Walker, P., Diamantea, F., Calverley, P. M., & Davies, L. (2005). Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Thorax, 60(9), 713–717. doi:10.1136/thx.2004.036046.
Eastham, K. M., Fall, A. J., Mitchell, L., & Spencer, D. A. (2004). The need to redefine non-cystic fibrosis bronchiectasis in childhood. Thorax, 59(4), 324–327. doi:10.1136/thx.2003.011577.
Edwards, L., Shirtcliffe, P., Wadsworth, K., Healy, B., Jefferies, S., Weatherall, M., et al. (2013). Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: A randomised double-blind placebo-controlled trial. Thorax. doi:10.1136/thoraxjnl-2012-202225.
Effing, T. (2012). Action plans and case manager support may hasten recovery of symptoms following an acute exacerbation in patients with chronic obstructive pulmonary disease (COPD). Journal of Physiotherapy, 58(1), 60. doi:10.1016/s1836-9553(12)70076-0.
Elborn, J. S., Perrett, J., Forsman-Semb, K., Marks-Konczalik, J., Gunawardena, K., & Entwistle, N. (2012). Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. The European Respiratory Journal, 40(4), 969–976. doi:10.1183/09031936.00194611.
Ferkol, T., Rosenfeld, M., & Milla, C. E. (2006). Cystic fibrosis pulmonary exacerbations. The Journal of Pediatrics, 148(2), 259–264. doi:10.1016/j.jpeds.2005.10.019.
Findley, L. J., & Sahn, S. A. (1981). The value of chest roentgenograms in acute asthma in adults. Chest, 80(5), 535–536.
Fireman, P. (2003). Understanding asthma pathophysiology. Allergy and Asthma Proceedings: The Official Journal of Regional and State Allergy Societies, 24(2), 79–83.
Flor-Escriche, X., Rodriguez-Mas, M., Espiau, M., Castan-Ensenat, X., Vigata-Reig, J. M., Poblet-Cortes, R., et al. (2011). Compliance with guidelines in the treatment of asthma exacerbations in primary care. Therapeutic Advances in Respiratory Disease, 5(6), 369–375. doi:10.1177/1753465811416698.
Friege, B., Friege, L., Pelz, J., Weber, M., von Spiegel, T., & Schroder, S. (2009). Bronchial asthma and chronic obstructive pulmonary disease with acute exacerbation: Preclinical differential diagnostic and emergency treatment. Anaesthesist, 58(6), 611–622. doi:10.1007/s00101-009-1536-x.
From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. Available from: http://www.ginasthma.org/. 2012.
Gandia, F., Guenard, H., Sriha, B., Tabka, Z., & Rouatbi, S. (2012). Inhaled magnesium sulphate in the treatment of bronchial hyperresponsiveness. Magnesium Research. doi:10.1684/mrh.2012.0323.
Garcha, D. S., Thurston, S. J., Patel, A. R. C., Mackay, A. J., Goldring, J. J. P., Donaldson, G. C., et al. (2012). Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax, 67(12), 1075–1080. doi:10.1136/thoraxjnl-2012-201924.
Gent, J. F., Belanger, K., Triche, E. W., Bracken, M. B., Beckett, W. S., & Leaderer, B. P. (2009). Association of pediatric asthma severity with exposure to common household dust allergens. Environmental Research, 109(6), 768–774. doi:10.1016/j.envres.2009.04.010.
Gentile, N. T., Ufberg, J., Barnum, M., McHugh, M., & Karras, D. (2003). Guidelines reduce x-ray and blood gas utilization in acute asthma. The American Journal of Emergency Medicine, 21(6), 451–453.
Gjoerup, J., Hilberg, O., & Bendstrup, E. (2012). Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults. Respirology, 17(6), 927–932. doi:10.1111/j.1440-1843.2012.02189.x.
Goeminne, P., & Dupont, L. (2010). Non-cystic fibrosis bronchiectasis: Diagnosis and management in 21st century. Postgraduate Medical Journal, 86(1018), 493–501. doi:10.1136/pgmj.2009.091041.
Goss, C. H., & Burns, J. L. (2007). Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis. Thorax, 62(4), 360–367. doi:10.1136/thx.2006.060889.
Gowers, A. M., Cullinan, P., Ayres, J. G., Anderson, H. R., Strachan, D. P., Holgate, S. T., et al. (2012). Does outdoor air pollution induce new cases of asthma? Biological plausibility and evidence; a review. Respirology, 17(6), 887–898. doi:10.1111/j.1440-1843.2012.02195.x.
Graham, V., Lasserson, T., & Rowe, B. H. (2001). Antibiotics for acute asthma. Cochrane Database of Systematic Reviews, 3, CD002741. doi:10.1002/14651858.cd002741.
Group, C. I. A. S. (1994). In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest, 105(5), 1411–1419.
Gupta, S., Siddiqui, S., Haldar, P., Raj, J. V., Entwisle, J. J., Wardlaw, A. J., et al. (2009). Qualitative analysis of high-resolution CT scans in severe asthma. Chest, 136(6), 1521–1528. doi:10.1378/chest.09-0174.
Guran, T., Ersu, R., Karadag, B., Nuri Akpinar, I., Yanikkaya Demirel, G., Hekim, N., et al. (2007). Association between inflammatory markers in induced sputum and clinical characteristics in children with non-cystic fibrosis bronchiectasis. Pediatric Pulmonology, 42(4), 362–369. doi:10.1002/ppul.20587.
Halbert, R. J., Natoli, J. L., Gano, A., Badamgarav, E., Buist, A. S., & Mannino, D. M. (2006). Global burden of COPD: Systematic review and meta-analysis. The European Respiratory Journal, 28(3), 523–532. doi:10.1183/09031936.06.00124605.
Hargreave, F. E. (2007). Quantitative sputum cell counts as a marker of airway inflammation in clinical practice. Current Opinion in Allergy and Clinical Immunology, 7(1), 102–106. doi:10.1097/ACI.0b013e328013e3c2.
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., et al. (2010). Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 363(12), 1128–1138. doi:10.1056/NEJMoa0909883.
Indinnimeo, L., Tancredi, G., Barreto, M., De Castro, G., Zicari, A. M., Monaco, F., et al. (2007). Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up. International Journal of Immunopathology and Pharmacology, 20(4), 841–845.
Jat, K. R., & Chawla, D. (2012). Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews, 11, CD009293. doi:10.1002/14651858.CD009293.pub2.
Kapur, N., Masters, I. B., & Chang, A. B. (2009). Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations. Respiratory Medicine, 103(11), 1681–1687. doi:10.1016/j.rmed.2009.05.007.
Kapur, N., Masters, I. B., & Chang, A. B. (2010). Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis what influences lung function stability? CHEST Journal, 138(1), 158–164. doi:10.1378/chest.09-2932.
Kapur, N., Masters, I. B., Morris, P. S., Galligan, J., Ware, R., & Chang, A. B. (2012). Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatric Pulmonology, 47(1), 68–75. doi:10.1002/ppul.21518.
Kelleher, D. L., Mehta, R. S., Jean-Francois, B. M., Preece, A. F., Blowers, J., Crater, G. D., et al. (2012). Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: A randomized crossover trial. PloS One, 7(12), e50716. doi:10.1371/journal.pone.0050716.
Kellett, F., & Robert, N. M. (2011). Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respiratory Medicine, 105(12), 1831–1835. doi:10.1016/j.rmed.2011.07.019.
Kellett, F., Redfern, J., & Niven, R. M. (2005). Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respiratory Medicine, 99(1), 27–31.
Ko, F. W. S., & Hui, D. S. C. (2012). Air pollution and chronic obstructive pulmonary disease. Respirology, 17(3), 395–401. doi:10.1111/j.1440-1843.2011.02112.x.
Koziol-White, C. J., & Panettieri, R. A., Jr. (2011). Airway smooth muscle and immunomodulation in acute exacerbations of airway disease. Immunological Reviews, 242(1), 178–185. doi:10.1111/j.1600-065X.2011.01022.x.
Langley, S. J., Goldthorpe, S., Craven, M., Woodcock, A., & Custovic, A. (2005). Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitised, atopic asthmatic subjects. Thorax, 60(1), 17–21. doi:10.1136/thx.2004.027839.
Lasserson, T., Holt, K., Evans, D., & Greenstone, M. (2001). Anticholinergic therapy for bronchiectasis. Cochrane Database of Systematic Reviews, 4, CD002163. doi:10.1002/14651858.cd002163.
Mallia, P., Message, S. D., Gielen, V., Contoli, M., Gray, K., Kebadze, T., et al. (2011). Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. American Journal of Respiratory and Critical Care Medicine, 183(6), 734–742. doi:10.1164/rccm.201006-0833OC.
Mallia, P., Footitt, J., Sotero, R., Jepson, A., Contoli, M., Trujillo-Torralbo, M. B., et al. (2012). Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 186(11), 1117–1124. doi:10.1164/rccm.201205-0806OC.
Marchant, J. M., Masters, I. B., Taylor, S. M., Cox, N. C., Seymour, G. J., & Chang, A. B. (2006). Evaluation and outcome of young children with chronic cough. CHEST Journal, 129(5), 1132–1141. doi:10.1378/chest.129.5.1132.
Marchant, J. M., Gibson, P. G., Grissell, T. V., Timmins, N. L., Masters, I. B., & Chang, A. B. (2008). Prospective assessment of protracted bacterial bronchitis: Airway inflammation and innate immune activation. Pediatric Pulmonology, 43(11), 1092–1099. doi:10.1002/ppul.20906.
Marchant, J., Masters, I. B., Champion, A., Petsky, H., & Chang, A. B. (2012). Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. Thorax, 67(8), 689–693. doi:10.1136/thoraxjnl-2011-201506.
Masoli, M., Fabian, D., Holt, S., & Beasley, R. (2004). The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy, 59(5), 469–478.
Mathew, S., Zeitlin, D., & Rickett, K. (2012). Clinical Inquiry: Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? The Journal of Family Practice, 61(9), 561–573.
McDonald, V. M., & Gibson, P. G. (2012). Exacerbations of severe asthma. Clinical and Experimental Allergy, 42(5), 670–677. doi:10.1111/j.1365-2222.2012.03981.x.
McGarvey, J. M., & Pollack, C. V. (2008). Heliox in airway management. Emergency Medicine Clinics of North America, 26(4), 905–920. doi:10.1016/j.emc.2008.07.007. viii.
Metersky, M. L., & O’Donnell, A. E. (2012). Preface. Bronchiectasis. Clinics in Chest Medicine, 33(2), xi–xii. doi:10.1016/j.ccm.2012.04.002.
Meyer, K. C. (2007). Bronchoalveolar lavage as a diagnostic tool. Seminars in Respiratory and Critical Care Medicine, 28(5), 546–560. doi:10.1055/s-2007-991527.
Meyer, K. C., Raghu, G., Baughman, R. P., Brown, K. K., Costabel, U., du Bois, R. M., et al. (2012). An official American Thoracic Society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine, 185(9), 1004–1014. doi:10.1164/rccm.201202-0320ST.
Mitra, A., Bassler, D., Goodman, K., Lasserson, T. J., & Ducharme, F. M. (2005). Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews, 2, CD001276. doi:10.1002/14651858.CD001276.pub2.
Mortensen, J., Hansen, A., Falk, M., Nielsen, I. K., & Groth, S. (1993). Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest, 103(3), 805–811.
Murray, M. P., Pentland, J. L., & Hill, A. T. (2009a). A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. European Respiratory Journal, 34(5), 1086–1092. doi:10.1183/09031936.00055509.
Murray, M. P., Turnbull, K., MacQuarrie, S., & Hill, A. T. (2009b). Assessing response to treatment of exacerbations of bronchiectasis in adults. European Respiratory Journal, 33(2), 312–318. doi:10.1183/09031936.00122508.
Nair, P., & Hargreave, F. E. (2010). Measuring bronchitis in airway diseases: Clinical implementation and application: Airway hyperresponsiveness in asthma: Its measurement and clinical significance. Chest, 138(2 Suppl), 38S–43S. doi:10.1378/chest.10-0094.
Nair, G. B., & Ilowite, J. S. (2012). Pharmacologic agents for mucus clearance in bronchiectasis. Clinics in Chest Medicine, 33(2), 363–370. doi:10.1016/j.ccm.2012.02.008.
O’Byrne, P. M., Pedersen, S., Lamm, C. J., Tan, W. C., Busse, W. W., & Group, o. b. o. t. S. I. (2009). Severe exacerbations and decline in lung function in asthma. American Journal of Respiratory and Critical Care Medicine, 179(1), 19–24. doi:10.1164/rccm.200807-1126OC.
O’Donnell, D. E. (2006). Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society, 3(2), 180–184. doi:10.1513/pats.200508-093DO.
Patel, I. S., Vlahos, I., Wilkinson, T. M., Lloyd-Owen, S. J., Donaldson, G. C., Wilks, M., et al. (2004). Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 170(4), 400–407. doi:10.1164/rccm.200305-648OC.
Patick, A. K. (2006). Rhinovirus chemotherapy. Antiviral Research, 71(2–3), 391–396. doi:10.1016/j.antiviral.2006.03.011.
Pizzutto, S. J., Grimwood, K., Bauert, P., Schutz, K. L., Yerkovich, S. T., Upham, J. W., et al. (2013). Bronchoscopy contributes to the clinical management of indigenous children newly diagnosed with bronchiectasis. Pediatric Pulmonology, 48(1), 67–73. doi:10.1002/ppul.22544.
Powell, C., Dwan, K., Milan, S. J., Beasley, R., Hughes, R., Knopp-Sihota, J. A., et al. (2012). Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews, 12, CD003898. doi:10.1002/14651858.CD003898.pub5.
Puderbach, M., & Eichinger, M. (2010). The role of advanced imaging techniques in cystic fibrosis follow-up: Is there a place for MRI? Pediatric Radiology, 40(6), 844–849. doi:10.1007/s00247-010-1589-7.
Quint, J. K., Donaldson, G. C., Goldring, J. J. P., Baghai-Ravary, R., Hurst, J. R., & Wedzicha, J. A. (2010). Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. CHEST Journal, 137(4), 812–822. doi:10.1378/chest.09-1541.
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., et al. (2009). An Official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. American Journal of Respiratory and Critical Care Medicine, 180(1), 59–99. doi:10.1164/rccm.200801-060ST.
Restrepo, R. D. (2007). Inhaled adrenergics and anticholinergics in obstructive lung disease: Do they enhance mucociliary clearance? Respiratory Care, 52(9), 1159–1173. discussion 1173–1155.
Ristovski, Z. D., Miljevic, B., Surawski, N. C., Morawska, L., Fong, K. M., Goh, F., et al. (2012). Respiratory health effects of diesel particulate matter. Respirology, 17(2), 201–212. doi:10.1111/j.1440-1843.2011.02109.x.
Robroeks, C. M., van Vliet, D., Jobsis, Q., Braekers, R., Rijkers, G. T., Wodzig, W. K., et al. (2012). Prediction of asthma exacerbations in children: Results of a one-year prospective study. Clinical and Experimental Allergy, 42(5), 792–798. doi:10.1111/j.1365-2222.2012.03992.x.
Rogers, D. F. (2007). Mucoactive agents for airway mucus hypersecretory diseases. Respiratory Care, 52(9), 1176–1197.
Rubin, B. K. (2002). The pharmacologic approach to airway clearance: Mucoactive agents. Respiratory Care, 47(7), 818–822.
Santus, P., Russo, A., Madonini, E., Allegra, L., Blasi, F., Centanni, S., et al. (2012). How air pollution influences clinical management of respiratory diseases. A case-crossover study in Milan. Respiratory Research, 13, 95. doi:10.1186/1465-9921-13-95.
Sherman, S., Skoney, J. A., & Ravikrishnan, K. P. (1989). Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. Archives of Internal Medicine, 149(11), 2493–2496.
Silverman, R. A., Foley, F., Dalipi, R., Kline, M., & Lesser, M. (2012). The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: A pilot study. Respiratory Medicine, 106(8), 1096–1102.
Simpson, B. M., Custovic, A., Simpson, A., Hallam, C. L., Walsh, D., Marolia, H., et al. (2001). NAC Manchester Asthma and Allergy Study (NACMAAS): Risk factors for asthma and allergic disorders in adults. Clinical and Experimental Allergy, 31(3), 391–399.
Simpson, J. L., Phipps, S., & Gibson, P. G. (2009). Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis. Pharmacology and Therapeutics, 124(1), 86–95. doi:10.1016/j.pharmthera.2009.06.004.
Snow, V., Lascher, S., Mottur-Pilson, C., Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest, P., & The American College of Physicians-American Society of Internal, M. (2001). Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine, 134(7), 595–599.
Song, W. J., & Chang, Y. S. (2012). Magnesium sulfate for acute asthma in adults: A systematic literature review. Asia Pacific Allergy, 2(1), 76–85. doi:10.5415/apallergy.2012.2.1.76.
Southern, K. W., Barker, P. M., Solis-Moya, A., & Patel, L. (2012). Macrolide antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews, 11, CD002203. doi:10.1002/14651858.CD002203.pub4.
Staggs, L., Peek, M., Southard, G., Gracely, E., Baxendale, S., Cross, K. P., et al. (2012). Evaluating the length of stay and value of time in a pediatric emergency department with two models by comparing two different albuterol delivery systems. Journal of Medical Economics, 15(4), 704–711. doi:10.3111/13696998.2012.674587.
Stenbit, A. E., & Flume, P. A. (2011). Pulmonary exacerbations in cystic fibrosis. Current Opinion in Pulmonary Medicine, 17(6), 442–447. doi:10.1097/MCP.0b013e32834b8c04.
Stevens, D. A., Schwartz, H. J., Lee, J. Y., Moskovitz, B. L., et al. (2000). A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. The New England Journal of Medicine, 342(11), 756–762.
Strek, M. E. (2012). Improving asthma management written asthma action plan time for an action plan. CHEST Journal, 142(5), 1085–1087. doi:10.1378/chest.12-1115.
Sullivan, S. D., Ramsey, S. D., & Lee, T. A. (2000). The economic burden of COPD. Chest, 117(2 Suppl), 5S–9S.
Teoh, L., Cates, C. J., Hurwitz, M., Acworth, J. P., van Asperen, P., & Chang, A. B. (2012). Anticholinergic therapy for acute asthma in children. Cochrane Database of Systematic Reviews, 4, CD003797. doi:10.1002/14651858.CD003797.pub2.
The air quality health index and asthma morbidity: A population-based study. (2013). Environ Health Perspect, 121(1), 46–52. doi:10.1289/ehp.1104816.
Thomas, R. A., Green, R. H., Brightling, C. E., Birring, S. S., Parker, D., Wardlaw, A. J., et al. (2004). The influence of age on induced sputum differential cell counts in normal subjects. Chest, 126(6), 1811–1814. doi:10.1378/chest.126.6.1811.
Trappenburg, J. C., Monninkhof, E. M., Bourbeau, J., Troosters, T., Schrijvers, A. J., Verheij, T. J., et al. (2011). Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: A multicentre randomised controlled trial. Thorax, 66(11), 977–984. doi:10.1136/thoraxjnl-2011-200071.
van der Valk, R. J., Baraldi, E., Stern, G., Frey, U., & de Jongste, J. C. (2012). Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy, 67(2), 265–271. doi:10.1111/j.1398-9995.2011.02734.x.
Vogelmeier, C., Aquino, T. O., O’Brien, C. D., Perrett, J., & Gunawardena, K. A. (2012). A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD, 9(2), 111–120. doi:10.3109/15412555.2011.641803.
Vollenweider, D. J., Jarrett, H., Steurer-Stey, C. A., Garcia-Aymerich, J., & Puhan, M. A. (2012). Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 12, CD010257. doi:10.1002/14651858.cd010257.
Wagener, J. S., & Kupfer, O. (2012). Dornase alfa (Pulmozyme). Current Opinion in Pulmonary Medicine, 18(6), 609–614. doi:10.1097/MCP.0b013e328358d51f.
Walters, J. A., Gibson, P. G., Wood-Baker, R., Hannay, M., & Walters, E. H. (2009). Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 1, CD001288. doi:10.1002/14651858.CD001288.pub3.
Wang, F., He, X. Y., Baines, K. J., Gunawardhana, L. P., Simpson, J. L., Li, F., et al. (2011). Different inflammatory phenotypes in adults and children with acute asthma. The European Respiratory Journal, 38(3), 567–574. doi:10.1183/09031936.00170110.
Wat, D., Gelder, C., Hibbitts, S., Cafferty, F., Bowler, I., Pierrepoint, M., et al. (2008). The role of respiratory viruses in cystic fibrosis. Journal of Cystic Fibrosis, 7(4), 320–328. doi:10.1016/j.jcf.2007.12.002.
Wedzicha, J. A. (2002). Exacerbations: Etiology and pathophysiologic mechanisms. CHEST Journal, 121(5_suppl), 136S–141S.
Wedzicha, J. A., & Donaldson, G. C. (2012). Natural history of successive COPD exacerbations. Thorax, 67(11), 935–936. doi:10.1136/thoraxjnl-2012-202087.
Weycker, D., Edelsberg, J., Oster, G., & Tino, G. (2005). Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine, 12(4), 205–209.
WHO. Asthma definition. http://www.who.int/respiratory/asthma/definition/en/
WHO. COPD definition. http://www.who.int/respiratory/copd/definition/en/index.html
Wong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H., et al. (2012) Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. The Lancet, 380(9842), 660–667. doi:10.1016/s0140-6736(12)60953-2.
Wurzel, D., Marchant, J. M., Yerkovich, S. T., Upham, J. W., Masters, I. B., & Chang, A. B. (2011). Short courses of antibiotics for children and adults with bronchiectasis. Cochrane Database of Systematic Reviews, 6, CD008695. doi:10.1002/14651858.CD008695.pub2.
Yerkovich, S., Hales, B., Carroll, M., Burel, J., Towers, M., Smith, D., et al. (2012). Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation. BMC Pulmonary Medicine, 12(1), 37.
Zirbes, J. M., & Milla, C. E. (2008). Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatric Pulmonology, 43(6), 607–610. doi:10.1002/ppul.20804.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this entry
Cite this entry
Goyal, V., Chang, A.B. (2016). Acute Exacerbations of Airway Inflammation. In: Parnham, M.J. (eds) Compendium of Inflammatory Diseases. Springer, Basel. https://doi.org/10.1007/978-3-7643-8550-7_196
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8550-7_196
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-7643-8530-9
Online ISBN: 978-3-7643-8550-7
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences